Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026
Madrigal Pharmaceuticals (Nasdaq: MDGL) will release first-quarter 2026 financial results on Wednesday, May 6, 2026, prior to the U.S. market open.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Madrigal Pharmaceuticals (Nasdaq: MDGL) will release first-quarter 2026 financial results on Wednesday, May 6, 2026, prior to the U.S. market open. Management will host a live webcast at 8:00 a.m. Eastern Time to review financial and operating results, accessible via the company Investor Relations website.
The live webcast is recommended to be accessed by registering at least 15 minutes early and will be available on-demand about two hours after the live event.
Details
News Market Reaction – MDGL
On Apr 22, the day this news came out, MDGL closed 0.27% above the previous close.
Data tracked by StockTitan Argus for the Apr 22 session.
Key Figures
- Earnings release date
- May 6, 2026
- First-quarter 2026 financial results release before U.S. market open
- Webcast time
- 8:00 a.m. Eastern Time
- Management webcast to review Q1 2026 results
- Registration lead time
- 15 minutes
- Recommended minimum time before webcast start to register
- Webcast replay delay
- 2 hours
- Time after live webcast when replay becomes available
Previous Earnings date Reports
-
Set Q4 and full-year 2025 results date and webcast details.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CONSHOHOCKEN, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2026 financial results on Wednesday, May 6, 2026, prior to the open of the U.S. financial markets.
Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.
The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
The webcast will be available approximately two hours after the live webcast.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com
Media Contact
Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.